Gut

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jonkers, I J A M
Right arrow Articles by Masclee, A A M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jonkers, I J A M
Right arrow Articles by Masclee, A A M
Gut 2003;52:109-115
© 2003 by Gut


BILIARY DISEASE

Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil

I J A M Jonkers1, A H M Smelt1, M Ledeboer2, M E Hollum1, I Biemond2, F Kuipers3, F Stellaard3, R Boverhof3, A E Meinders1, C H B W Lamers2, A A M Masclee2

1 Department of General Internal Medicine, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, the Netherlands
2 Department of Gastroenterology, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, the Netherlands
3 Centre for Liver, Intestinal, and Metabolic Diseases, Academic Hospital Groningen, Groningen, the Netherlands

Correspondence to:
Correspondence to:
Dr A H M Smelt, Department of General Internal Medicine, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, the Netherlands;
A.H.M.Smelt{at}lumc.nl


ABSTRACT
Background and aim: The aim of this study was to unravel the mechanisms responsible for the increased risk of gall stone disease in hypertriglyceridaemia (HTG) and to compare the effects of triglyceride lowering therapy by bezafibrate and fish oil on determinants of cholelithiasis (biliary lipid composition and gall bladder motility) in HTG patients.

Patients and methods: Gall bladder motility (ultrasonography) was studied postprandially and during infusion of cholecystokinin (CCK). Determinants of cholelithiasis and serum lipids were compared between nine HTG patients and 10 age, sex, and body mass index matched normolipidaemic controls. The effects of bezafibrate and fish oil in HTG patients were studied in a randomised cross over trial.

Results: HTG patients showed 14-fold higher serum triglyceride (TG) levels than controls. Biliary lipid composition, fasting gall bladder volumes, and CCK levels did not differ between HTG patients and controls. Gall bladder emptying was reduced in HTG patients compared with controls during CCK infusion (-22%) as well as in response to a meal (-37%; both p<0.001). Postprandial CCK levels were significantly higher in HTG patients. Both bezafibrate and fish oil reduced serum TG levels (-68% and -51% v baseline, respectively; both p<0.01). Fasting CCK levels were not affected whereas CCK induced gall bladder emptying increased during bezafibrate (+29%; p<0.001) and tended to increase on fish oil therapy (+13%; p=0.07). Postprandial gall bladder motility improved on bezafibrate and fish oil (+47 and +25% v baseline, respectively; both p<0.02) at least partly due to increased gall bladder sensitivity to CCK (both p<0.05 v baseline). Bezafibrate but not fish oil increased the molar ratio of cholesterol to bile acids (+40%; p<=0.05) but no effects on cholesterol saturation index were seen with either treatment.

Conclusions: We suggest that impaired gall bladder motility occurs in HTG patients due to decreased sensitivity to CCK, which may add to the enhanced risk of gall stone disease in HTG patients. Triglyceride lowering therapy by both fish oil and bezafibrate improve gall bladder dysmotility without adversely affecting biliary cholesterol saturation.


Keywords: gall bladder emptying; cholelithiasis; triglycerides; cholecystokinin; bezafibrate; fish oil

Abbreviations: HTG, hypertriglyceridaemia; CCK, cholecystokinin; TG, triglyceride; (V)LDL, (very) low density lipoprotein; HDL, high density lipoprotein; CSI, cholesterol saturation index; BMI, body mass index




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
M. O. Weickert, M. Mohlig, J. Spranger, C. Schofl, C. V. Loeffelholz, R. L. Riepl, B. Otto, and A. F. H. Pfeiffer
Effects of Euglycemic Hyperinsulinemia and Lipid Infusion on Circulating Cholecystokinin
J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2328 - 2333.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
I. J. A. M. Jonkers, A. H. M. Smelt, H. M. G. Princen, F. Kuipers, J. A. Romijn, R. Boverhof, A. A. M. Masclee, and F. Stellaard
Fish Oil Increases Bile Acid Synthesis in Male Patients with Hypertriglyceridemia
J. Nutr., April 1, 2006; 136(4): 987 - 991.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2003 BMJ Publishing Group Ltd & British Society of Gastroenterology